Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Tempest Therapeutics, Inc.(TPST US)

$0.51-0.012.16%Ext:$0.64+0.1325.76%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
TPST US​

Tempest Therapeutics, Inc. — Company Profile

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
Headquarters
CA, US

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

Location
CA, US
Employees0
Sector
Health Care
Industry
Pharmaceuticals

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1K)

Expand
  • DEFA14ACURRENT REPORT20 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders20 Oct
  • 8-KPRESS RELEASE, DATED OCTOBER 14, 2026, FURNISHED HEREWITH19 Oct
  • PRE 14APRELIMINARY PROXY STATEMENT16 Oct
  • DRule 506(b) provides a "safer harbor" for a private offering13 Oct
  • 4Smith Nancy Freda2 Oct
  • 3Smith Nancy Freda2 Oct
  • 424B3PROSPECTUS2 Oct
  • EFFECTNotice of effectiveness2 Oct
  • 8-KPRESS RELEASE, DATED SEPTEMBER 23, 2026, FURNISHED HEREWITH28 Sep
  • S-3REGISTRATION STATEMENT25 Sep
  • 8-KTempest Secures Exclusive Option to License Clinical-StageCD7-TargetedLentiviral In VivoCAR-TPlatform17 Sep
  • DEFA14ADefinitive additional materials16 Sep
  • 8-KSubmission of Matters to a Vote of Security Holders16 Sep
  • 8-KEntry into a Material Definitive Agreement15 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))1 Sep
  • EFFECTNotice of effectiveness1 Sep
  • CORRESPFiling review correspondence27 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Aug
  • S-1Registration statement (general form)21 Aug

News

  • Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise14 Oct
  • Tempest signs related-party R&D pact, reshapes leadership29 Sep
  • Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors23 Sep
  • Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket16 Sep
  • Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform15 Sep
  • Tempest Therapeutics Announces Up to $7.5 Million Private Placement11 Sep
  • Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference8 Sep
  • Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update13 Aug

Mentions in Filings

  • ?
    August 27, 2026 Matthew Angel Chief Executive Officer and President <strong>Tempest Therapeutics, Inc.</strong> 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-1 Filed August 21, 2026 File No. 333-298498 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelerat …
    Tempest Therapeutics, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·27 Aug·27 Aug
  • ?
    August 27, 2026 Matthew Angel Chief Executive Officer and President <strong>Tempest Therapeutics, Inc.</strong> 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-1 Filed August 21, 2026 File No. 333-298498 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. …
    Tempest Therapeutics, Inc.·LETTER - UPLOAD - Filing review upload·27 Aug·27 Aug
  • #\*Teladoc Health, Inc. 454,835 2,478,851 Teleflex, Inc. 20,123 2,100,238 \*Tempest Therapeutics, Inc. 107 291
    Dimensional ETF TrustTempest Therapeutics, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … ##### Table of Contents | | | | | | | --- | --- | --- | --- | --- | | **Closed Date** | **Surviving Company** | **Public Company** | **Value Delivered for Public Vehicle8 Net of Cash ($M)** | | | 6/28/2021 | <strong>Tempest Therapeutics</strong> Inc. | Millendo Therapeutics, Inc. (Nasdaq: MLND) | | 19 | | 6/15/2021 | ReShape Lifesciences Inc. | Obalon Therapeutics, Inc. (Nasdaq: OBLN) | | 15 | | 4/27/2021 | Leading BioSciences, Inc. (Palisade) | Seneca Biopharma …
    Sonic Holdco, Inc.Tempest Therapeutics, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·16 Oct
  • … sdaq: ARPO) | | 15 | | 8/3/2021 | Decoy Biosystems, Inc. | Indaptus Therapeutics (Intec) (Nasdaq: INDP) | | 10 | | 7/27/2021 | Cytocom, Inc. (Statera) | Cleveland BioLabs, Inc. (Nasdaq: CBLI) | | NA | | 6/28/2021 | <strong>Tempest Therapeutics</strong> Inc. | Millendo Therapeutics, Inc. (Nasdaq: MLND) | | 19 | | 6/15/2021 | ReShape Lifesciences Inc. | Obalon Therapeutics, Inc. (Nasdaq: OBLN) | | 15 | | 4/27/2021 | Leading BioSciences, Inc. (Palisade) | Seneca Bio …
    Boundless Bio, Inc.Tempest Therapeutics, Inc.·S-4 - Registration statement (business combination)·Q4 26·8 Oct
  • … sdaq: ARPO) | | 15 | | 8/3/2021 | Decoy Biosystems, Inc. | Indaptus Therapeutics (Intec) (Nasdaq: INDP) | | 10 | | 7/27/2021 | Cytocom, Inc. (Statera) | Cleveland BioLabs, Inc. (Nasdaq: CBLI) | | NA | | 6/28/2021 | <strong>Tempest Therapeutics</strong> Inc. | Millendo Therapeutics, Inc. (Nasdaq: MLND) | | 19 | | 6/15/2021 | ReShape Lifesciences Inc. | Obalon Therapeutics, Inc. (Nasdaq: OBLN) | | 15 | | 4/27/2021 | Leading BioSciences, Inc. (Palisade) | Seneca Bio …
    InMed Pharmaceuticals Inc.Tempest Therapeutics, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q2 27·1 Oct

Key Stats

Trading

Px/Chg 1D$0.00 / +0.00%
52 Wk H$0.00
52 Wk L$0.00
Avg Volume0.00
Beta0.00
Mkt Cap0.00

Float

0
Short Float0.00%
Days to Cover0.00
Stock Repurchased$0.00

Estimates

P/E0.00
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-6.24-0.66-23.58-4.58-1.90-0.47
Price / Sales0.000.000.000.000.000.00
Price / Book Value10.841.3125.9810.021.1515.77
Price / Free Cash Flow-7.12-0.75-25.26-5.73-2.14-1.71
ENTERPRISE VALUE METRICS
Enterprise Value179.114.5676.9176.88.119.0
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-6.41-0.43-24.47-4.40-2.04-0.69
Enterprise Value / EBIT-6.32-0.43-24.14-4.36-2.01-0.69

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—----0.4-
EBITDA-81.4%-26.6-33.5-27.7-40.1-25.8
EBIT-90.5%-27.0-34.1-28.0-40.5-26.1
Net Income-1.9%-28.3-35.7-29.5-41.8-26.3
EPS (Diluted)-5.1%-7.80-3.18-1.91-1.50-6.33
BALANCE SHEET
Cash & ST Inv-37.9%51.831.239.230.37.7
Total Assets-30.7%73.246.151.641.516.9
Total Liabilities-27.5%37.128.024.822.410.3
Total Shareholder Equity-34.5%36.118.126.819.16.7
CASH FLOW
Net Operating Cash Flow82.1%-26.0-31.1-27.4-33.0-26.8
Cap Ex—-0.1-0.6-0.2-0.4-
Free Cash Flow69%-26.1-31.6-27.5-33.5-26.8

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)0.51
Basic Shares15.98
Market Cap8.1
Diluted Shares10.93
Fully Diluted Shares Outstanding10.93
Fully Diluted Market Cap5.6
+Consolidated Debt7.9
−In-the-Money Convertible Debt—
+Capital Leases1.2
+Operating Leases—
−Cash & Equivalents-1.8
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value14.2

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US